Brief: Kamada Reiterates 2025 FY Revenue Guidance Of $178M-$182M

Kamada

08/12/2025 12:26

Dec 8 (Reuters) - Kamada Ltd KMDA.TA:

KAMADA ANNOUNCES DISCONTINUATION OF ITS PHASE 3 INHALED AAT CLINICAL TRIAL; REITERATES 2025 FULL-YEAR GUIDANCE AND PROJECTS DOUBLE-DIGIT GROWTH IN REVENUES AND PROFITABILITY IN 2026

KAMADA LTD - REITERATES 2025 FY REVENUE GUIDANCE OF $178M-$182M

KAMADA LTD - PROJECTS DOUBLE-DIGIT GROWTH IN REVENUES AND PROFITABILITY IN 2026

KAMADA LTD - TO DISCONTINUE PHASE 3 INHALED AAT TRIAL

KAMADA-BASED ON RESULTS OF PLANNED INTERIM FUTILITY ANALYSIS INHALED AAT TRIAL UNLIKELY TO SHOW STATISTICALLY SIGNIFICANT BENEFIT IN PRIMARY ENDPOINT

KAMADA LTD: CONTINUES TO SUPPLY GLASSIA, MARKETED INTERNATIONALLY INCLUDING IN U.S. & CANADA THROUGH LICENSE AGREEMENT WITH TAKEDA

Source text: ID:nGNX6cwJxM

Further company coverage: KMDA.TA

 ((Reuters.Briefs@thomsonreuters.com;))